Literature DB >> 23548450

Bipartite talus: a case series and algorithm for treatment.

B Rose1, C Southgate, L Louette.   

Abstract

BACKGROUND: Bipartite talus is a rare condition of uncertain aetiology, with various treatment options described.
METHODS: We report five symptomatic bipartite talus cases in four male patients warranting surgical management. All patients were reviewed by an independent assessor.
RESULTS: The youngest patient presented with bilateral lesions without sub-talar arthrosis. He was treated twice by internal fixation with bone grafting. The left side failed to unite. The second patient presented with isolated sub-talar osteoarthritis. He underwent fragment excision and sub-talar arthrodesis with bone graft. The third patient presented aged 55 with severe hind-foot osteoarthritis, and underwent tibio-talar-calcaneal fusion. The final patient was treated with fragment excision and sub-talar arthrodesis. All patients reported symptom improvement or resolution post-operatively. Four cases showed evidence of radiographic union.
CONCLUSIONS: We suggest a treatment rationale of fragment fusion if large enough, or excision if not, with associated limited fusion if the adjacent joints are markedly degenerate.
Copyright © 2012 European Foot and Ankle Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23548450     DOI: 10.1016/j.fas.2012.11.011

Source DB:  PubMed          Journal:  Foot Ankle Surg        ISSN: 1268-7731            Impact factor:   2.705


  2 in total

1.  Talus Partitus: a review of five cases diagnosed by MRI.

Authors:  Corbin L Pomeranz; William B Morrison; Vishal Desai; Adam C Zoga; Jeffrey A Belair
Journal:  Skeletal Radiol       Date:  2019-11-09       Impact factor: 2.199

Review 2.  Talus bipartitus: a systematic review and report of two cases with arthroscopic treatment.

Authors:  Ruben Zwiers; Peter A J de Leeuw; Gino M M J Kerkhoffs; C Niek van Dijk
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-06-28       Impact factor: 4.342

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.